Radford joins Nanosonics
Thursday, 05 June, 2008
Nanosonics Ltd (ASX: NAN) has appointed a new CEO to lead the disinfection technology company's latest product roll-out.
The new CEO, David Radford, has 20 years of experience in the medical device and healthcare industries. He also has an honours degree in applied biological science from Bristol Polytechnic.
The company said Radford has extensive experience driving rapid growth in the ultrasound product market, which makes him the perfect person to oversee the company's roll-out of its new ultrasound disinfection devices.
Radford takes the helm from Nanosonics CFO Chris Grundy, who had been acting as CEO, and from Dr David Fisher, who had taken on the role of interim executive director.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
